huzalt
Huzalt is a synthetic cannabinoid receptor agonist, also known as a designer drug, that has gained attention for its potential psychoactive effects. It was first identified in 2012 and has since been detected in various countries, including the United States, the United Kingdom, and Australia. Huzalt is structurally similar to other synthetic cannabinoids, such as JWH-018 and JWH-073, and is believed to act as an agonist at the cannabinoid CB1 receptor, which is found in the central nervous system.
The psychoactive effects of huzalt are thought to be similar to those of other synthetic cannabinoids, including
The use of huzalt is associated with several risks, including dependence, tolerance, and potential for overdose.